泛視神經脊髓炎（NMOSD）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計西班牙 NMOSD 市場將從 2025 年的 2,100 萬美元成長到 2035 年的 5,200 萬美元。
• 推動市場成長的因素如下：
• 標靶生技藥品和補體抑制劑的應用日益廣泛
• 診斷技術的進步與對疾病認知的提高
• 未來的成長取決於那些具有良好安全性並能持續預防復發的治療方法。

泛視神經脊髓炎（NMOSD）概述

泛視神經脊髓炎 (NMOSD) 是一種罕見且嚴重的自體免疫發炎性中樞神經系統疾病，主要涉及視神經和脊髓。此疾病是由致病性水通道蛋白 4 (AQP4-IgG) 自體抗體引起，這些抗體破壞血腦障壁中的星狀細胞。患者表現為嚴重的視神經炎，導致視力喪失；廣泛的橫貫性脊髓炎，涉及三個或更多椎體節段；以及後部區域症候群，導致頑固性呃逆和嘔吐。 AQP4-IgG 和 MOG-IgG 的血清學檢測對於鑑別 NMOSD 與多發性硬化症和 MOG-IgG 相關疾病 (MOGAD) 至關重要。急性發作的治療包括高劑量糖皮質激素和快速血漿置換。由於 NMOSD 的復發會導致累積和不可逆的損害，因此立即開始維持治療至關重要。已核准的標靶維持治療包括IL-6受體拮抗劑沙曲珠單抗、CD19 B細胞清除劑伊內利珠單抗以及補體抑制劑Eculizumab和長效拉維珠單抗。Rituximab仍是一種廣泛使用的仿單標示外標準治療藥物，而Rituximab尚未獲準用於治療該疾病。重要的是，維持治療方案的選擇必須考慮抗體狀態。雖然B細胞清除療法對AQP4陽性疾病非常有效，但在MOGAD患者中的失敗率很高，矛盾的是，它還存在加劇復發的風險。長期的多學科照護對於維持患者的功能獨立性至關重要。

主要亮點

• 據預測，德國的 NMOSD 病例數將從 2025 年的 3,363 例增加到 2035 年的 3,510 例。
• NMOSD 是一種罕見的中樞神經系統自體免疫疾病，其特徵是反覆發作的癲癇，導致嚴重的神經功能障礙。
• 儘管近年來治療方法取得了進展，但預防復發仍然是治療的首要任務。
• 目前仍有大量未被滿足的治療需求，即能夠持續預防復發並改善長期療效的治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Amgen
• Alexion Pharmaceuticals, Inc.
• Hoffmann-La Roche
• Beijing Mabworks Biotech Co., Ltd.
• Bio-Thera Solutions
• CorestemChemon, Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖的觀點。
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook

Thelansis's "Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential NMOSD treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuromyelitis Optica Spectrum Disorder (NMOSD) Overview

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, severe autoimmune inflammatory central nervous system disorder that predominantly targets the optic nerves and spinal cord. It is driven by pathogenic aquaporin-4 (AQP4-IgG) autoantibodies that destroy astrocytes at the blood-brain barrier. Patients present with severe optic neuritis causing visual loss, longitudinally extensive transverse myelitis spanning three or more vertebral segments, and area postrema syndrome causing intractable hiccups and vomiting. Serum testing for AQP4-IgG and MOG-IgG is mandatory to differentiate NMOSD from multiple sclerosis and MOG-IgG-associated disease (MOGAD). Acute attacks are managed with high-dose corticosteroids and prompt plasma exchange. Because NMOSD relapses cause cumulative, irreversible disability, immediate maintenance therapy is essential. Approved targeted maintenance options include the IL-6 receptor antagonist satralizumab, the CD19 B-cell depletor inebilizumab, and the complement inhibitors eculizumab and long-acting ravulizumab. While rituximab remains a widely utilized off-label standard, ublituximab is not approved for this condition. Crucially, maintenance selection must respect antibody status: while B-cell depletion is highly effective in AQP4-positive disease, it carries high failure rates and potential risk of paradoxically exacerbating relapses in MOGAD cohorts. Long-term multidisciplinary care is vital to preserve functional independence.

Key Highlights

• In Germany, prevalent NMOSD cases are projected to increase from 3,363 in 2025 to 3,510 by 2035.
• NMOSD is a rare autoimmune disorder of the central nervous system characterized by recurrent attacks causing severe neurological disability.
• Despite recent therapeutic advances, preventing relapses remains a major treatment priority.
• Significant unmet need remains for therapies that provide durable relapse prevention and improved long-term outcomes.

Market Overview

• The Spain NMOSD market is projected to grow from $21M in 2025 to $52M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologics and complement inhibitors
• Improved diagnosis and growing disease awareness
• Future growth will depend on therapies capable of achieving sustained relapse prevention with favorable safety profiles.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Amgen
• Alexion Pharmaceuticals, Inc.
• Hoffmann-La Roche
• Beijing Mabworks Biotech Co., Ltd.
• Bio-Thera Solutions
• CorestemChemon, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)